Clinical trial
A Phase II Study of Milataxel (TL139) Administered Orally in Patients With Malignant Mesothelioma
NCT00685204 is registered in ClinicalTrials.gov with Taxolog Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Milataxel (TL139) Administered Orally in Patients With Malignant Mesothelioma
- Lead sponsor
- Taxolog Inc.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- March 31, 2008
- Completion date
- Not reported
- Enrollment
- 90 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.